hPD-1(BALB/c)
Nomenclature
BALB/cAnSmoc-Pdcd1tm1(hPDCD1)Smoc
Cat. NO.
NM-HU-190079
Strain State
Repository Live
Model Description
Validation Data
Fig1. Expression of PD-1 in the activated spleen lymphocytes of homozygous humanized PD-1 BALB/c KI mice is detected by FACS.
Fig2. In vivo validation of homozygous BALB/c-hPD1 mice.
The homozygous BALB/c-hPD1 mice were inoculated with CT26 cells, and randomly assigned to different groups (n=7) when the tumor grew to a volume of 100 mm3. A combinatorial treatment of anti-hPD1 antibody Keytruda and entinostat (ENT; a class I HDAC inhibitor) demonstrated a noticeable efficacy improvement compared to the same dose of single agent (A) without affecting the animal body weight (B).
Fig3. In vivo validation of homozygous BALB/c-hPD1 mice.
The homozygous BALB/c-hPD1 mice were inoculated with CT26 cells, and randomly assigned to different groups (n=6) when the tumor grew to a volume of 65 mm3. A combinatorial treatment of anti-hPD1 antibody Opdivo and anti-mCTLA antibody demonstrated a noticeable efficacy improvement compared to the same dose of single agent (A) without affecting the animal body weight (B). (In collaboration with Crownbio)
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreSMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn more
